These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 38652426)

  • 1. Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape.
    Ghose A; Lapitan P; Apte V; Ghosh A; Kandala A; Basu S; Parkes J; Shinde SD; Boussios S; Sharma A; Das P; Vasdev N; Rebuzzi SE; Ürün Y; Kanesvaran R; Maniam A; Banna GL
    Curr Oncol Rep; 2024 Jun; 26(6):633-646. PubMed ID: 38652426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates in Urothelial Carcinomas.
    Sarfaty M; Rosenberg JE
    Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
    Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
    Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives.
    Tonni E; Oltrecolli M; Pirola M; Tchawa C; Roccabruna S; D'Agostino E; Matranga R; Piombino C; Pipitone S; Baldessari C; Bacchelli F; Dominici M; Sabbatini R; Vitale MG
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
    Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
    J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibody-Drug Conjugates against Urothelial Carcinoma-Current Issues and Future Development].
    Ikarashi D; Obara W
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):691-694. PubMed ID: 39191682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
    Hashimoto H; Tanaka Y; Murata M; Ito T
    Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacituzumab govitecan: an antibody-drug conjugate.
    Sahota S; Vahdat LT
    Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
    Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
    Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates in Prostate Cancer: Where Are we?
    Mjaess G; Aoun F; Rassy E; Diamand R; Albisinni S; Roumeguère T
    Clin Genitourin Cancer; 2023 Feb; 21(1):171-174. PubMed ID: 35999150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and future prospects of antibody-drug conjugates in urological malignancies.
    Hayashi T; Hinata N
    Int J Urol; 2022 Oct; 29(10):1100-1108. PubMed ID: 35581739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
    Singh AM; Guevara-Patino JA; Wang X; Li R; Sonpavde G; Jain RK
    BioDrugs; 2023 Jul; 37(4):505-520. PubMed ID: 37256534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
    Dri A; Arpino G; Bianchini G; Curigliano G; Danesi R; De Laurentiis M; Del Mastro L; Fabi A; Generali D; Gennari A; Guarneri V; Santini D; Simoncini E; Zamagni C; Puglisi F
    Cancer Treat Rev; 2024 Feb; 123():102672. PubMed ID: 38118302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging agents for the treatment of metastatic urothelial cancer.
    Kwon WA; Seo HK
    Investig Clin Urol; 2021 May; 62(3):243-255. PubMed ID: 33943047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ANTIBODY-DRUG CONJUGATES - A NOVEL APPROACH FOR THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA].
    Sternschuss M; Sarfaty M
    Harefuah; 2022 Jan; 161(1):49-54. PubMed ID: 35077061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.